Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
7 Results Found
AHA Details Legislative Priorities for Congressional Leaders
Hospitals and health systems are experiencing significant financial pressures that challenge their ability to provide 24/7 care for the patients and communities they serve. As Congress begins to focus on its end-of-the-year work, America’s hospitals and health systems respectfully request that you consider the following priorities.
AHA Letter to FTC and DOJ Re: Anticompetitive Activity by Drug Companies with Respect to 340B “Rebate Models”
AHA letter to the Federal Trade Commission and Department of Justice regarding anticompetitive activity by drug companies with respect to 340B “rebate models.”
AHA Comments to HRSA on Proposed 340B Rebate Model Pilot Program
AHA comments on the Health Resources and Services Administration’s notice of the 340B Rebate Model Pilot Program.
AHA, Health Associations Comment on HRSA Notice of a 340B Rebate Model Pilot Program
AHA, health associations initial comment on the Health Resources and Services Administration’s (HRSA) notice of a 340B Rebate Model Pilot Program.
AHA Urges HHS to Reject the Effort by Several Large Drug Companies to Undermine the 340B Drug Pricing Program
AHA urges Secretary U.S. Department of Health and Human Services to reject the effort by several large drug companies to undermine the 340B Drug Pricing Program by imposing a “rebate model,”
AHA Letter to CMS on Medicare Transaction Facilitator and Drug Negotiation Program
AHA shares feedback in response to the Centers for Medicare & Medicaid Services’ information collection request (ICR) regarding the Medicare Transaction Facilitator (MTF) and the Medicare drug negotiation program.
Deadline Extended Until Oct. 29 for Your Representatives to Sign ‘Dear Colleague’ Letter Urging HHS to Take Action
Please contact your representatives today and ask them to sign onto a bipartisan “Dear Colleague” letter to Department of Health and Human Services Secretary Alex Azar expressing concern about recent efforts by Kalderos to transition the 340B Drug Pricing Program from one of up-front discounts to post-sale rebates.